Ipilimumab + Androgen Depravation Therapy in Prostate Cancer
Status:
Terminated
Trial end date:
2017-04-07
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if ipilimumab in combination with either
Lupron® (leuprolide), Zoladex® (goserelin), or Firmagon® (degarelix) can affect
prostate-specific antigen (PSA) levels in patients with prostate cancer. Researchers also
want to learn if these drug combinations affect the body's immune system. The safety of these
drug combinations will also be studied.